IFP Energies nouvelles

IFPEN does not raise external funds. It uses roughly €300 million in annual public and industrial-contract revenue to operate labs and incubate ventures. A subsidiary, IFP Invest, takes equity stakes in the most commercially viable spin-offs, often alongside industrial partners like TotalEnergies or Axens. The structure functions like a permanent-capital venture builder backed by the French state.

Chevet chaired the French nuclear regulator (ASN) before taking the top role at IFPEN in 2015. A graduate of École Polytechnique and Mines Paris, he brought deep regulatory and engineering experience to an institution historically run by oil-refining scientists. Under his tenure IFPEN accelerated its pivot toward hydrogen, batteries, and carbon-capture ventures.

The most notable is Axens, the process-licensing firm that commercialized IFPEN's refining and petrochemical technologies and now generates over €800 million in annual revenue. Other active spin-outs include Enerstone (battery lifecycle analytics) and Arol Energy (biogas upgrading). Altogether IFPEN's portfolio holds equity in more than a dozen operating companies.

No. IFPEN's model is direct incubation and corporate venture, not fund-of-funds. It creates companies from its own labs, holds equity via IFP Invest, and may co-invest alongside industrial groups. It does not allocate capital to third-party venture capital managers.

IFPEN is a French EPIC — a public industrial and commercial establishment under the joint supervision of the Ministries of Energy, Research, and Economy. The French government appoints its chairman and approves its strategic contract every four years. Its budget is voted on by parliament as part of the national research allocation.

It avoids pure-software energy plays — its mandate requires hardware, chemistry, or physical engineering components. It does not invest outside energy applications, meaning no adjacencies into general climate-software or carbon-accounting platforms. It also avoids growth-stage capital, exiting positions as ventures become independently fundable.

IFPEN invented the underlying process technologies; Axens is the commercial entity that licenses them globally. IFPEN maintains a research pipeline while Axens pays licensing fees and royalties back to the institute. That recurring revenue from Axens alone funds a material portion of IFPEN's annual lab operations.